Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01768962 · ClinicalTrials.gov registry record · Phase 1
Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel
A Phase 1 study, sponsored by CONRAD.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01768962 is a Phase 1 study that has completed, run by CONRAD. The registered enrollment target is 14 participants.
The verdict
NCT01768962, a Phase 1 study, has completed, sponsored by CONRAD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
To compare local and systemic pharmacokinetics of tenofovir reduced-glycerin (TFV RG) 1% gel after 2 weeks of daily rectal use and after 2 weeks of daily vaginal use
Interventions
- DRUG Once Daily Application of TFV RG 1% Gel - Vaginal
- DRUG Once Daily Application of TFV RG 1% gel - Rectal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01768962
The ClinicalTrials.gov registry entry for NCT01768962 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CONRAD, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Once Daily Application of TFV RG 1% Gel - Vaginal is the first listed.
NCT01768962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01768962 about?
NCT01768962 is a clinical study titled "Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel". To compare local and systemic pharmacokinetics of tenofovir reduced-glycerin (TFV RG) 1% gel after 2 weeks of daily rectal use and after 2 weeks of daily vaginal use
What is the current status of trial NCT01768962?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2014-04. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01768962?
The interventions under investigation include: Once Daily Application of TFV RG 1% Gel - Vaginal (DRUG), Once Daily Application of TFV RG 1% gel - Rectal (DRUG).
Who is sponsoring clinical trial NCT01768962?
This trial is sponsored by CONRAD, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.